Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.59 USD | +1.90% | -4.82% | -35.34% |
Financials (USD)
Sales 2024 * | 114M | Sales 2025 * | 4.17M | Capitalization | 133M |
---|---|---|---|---|---|
Net income 2024 * | -71M | Net income 2025 * | -188M | EV / Sales 2024 * | 1.76 x |
Net Debt 2024 * | 67.55M | Net Debt 2025 * | 127M | EV / Sales 2025 * | 62.3 x |
P/E ratio 2024 * |
-1.48
x | P/E ratio 2025 * |
-0.78
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.05% |
Latest transcript on Gossamer Bio, Inc.
1 day | +1.90% | ||
1 week | -4.82% | ||
1 month | -16.90% | ||
3 months | -58.16% | ||
6 months | -24.57% | ||
Current year | -35.34% |
Managers | Title | Age | Since |
---|---|---|---|
Faheem Hasnain
CEO | Chief Executive Officer | 65 | 15-10-24 |
Bryan Giraudo
DFI | Director of Finance/CFO | 48 | 18-05-06 |
Chief Tech/Sci/R&D Officer | - | 23-10-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Faheem Hasnain
CEO | Chief Executive Officer | 65 | 15-10-24 |
Thomas Daniel
BRD | Director/Board Member | 70 | 17-12-31 |
Skye Drynan
BRD | Director/Board Member | 48 | Mar. 10 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.05% | 1,487 M€ | +7.77% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.59 | +1.90% | 865,704 |
24-05-30 | 0.579 | -0.87% | 531,458 |
24-05-29 | 0.5841 | -1.75% | 1,129,409 |
24-05-28 | 0.5945 | -4.10% | 1,647,587 |
24-05-24 | 0.6199 | -2.65% | 1,344,898 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.34% | 133M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- GOSS Stock